efavirenz has been researched along with Liver Dysfunction in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Branco, T; Caixas, U; Germano, I; Lampreia, F; Monteiro, EC; Papoila, AL; Pereira, SA | 1 |
| Pulido, F; Torralba, M | 1 |
| Boyd, MA; Cooper, DA; Dore, GJ; Duncombe, CJ; Lange, JM; Law, WP; Mahanontharit, A; Phanuphak, P; Ruxrungtham, K | 1 |
| Amador, C; Benito, C; Ena, J; Fenoll, V; Pasquau, F | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 1 |
| Antela, A; Aranzabal, L; Casado, JL; Diz, S; Dronda, F; Hernandez-Ranz, F; Marín, A; Moreno, A; Moreno, L; Moreno, S; Moya, J; Perez-Elias, MJ; Quereda, C | 1 |
| Donahue, JP; Erdem, H; George, AL; Haas, DW; Haines, JL; Kim, RB; Motsinger, AA; Raffanti, S; Rebeiro, P; Ritchie, MD; Sterling, TR | 1 |
| Aweeka, FT; Charlebois, E; Coates, C; Dorsey, G; German, P; Greenhouse, B; Havlir, D; Lindegardh, N; Rosenthal, PJ | 1 |
| Cecelia, AJ; Devaleenal, B; Flanigan, T; Kumarasamy, N; Mayer, KH; Muthu, S; Palanivel, V; Venkatesh, KK; Yepthomi, T | 1 |
| Frank, A; Katsounas, A; Klinker, H; Langmann, P | 1 |
| Lo Caputo, S; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
1 review(s) available for efavirenz and Liver Dysfunction
| Article | Year |
|---|---|
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2002 |
3 trial(s) available for efavirenz and Liver Dysfunction
| Article | Year |
|---|---|
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Female; Follow-Up Studies; Gynecomastia; HIV Infections; Humans; Hypersensitivity; Liver Diseases; Male; Metabolic Diseases; Nevirapine; Oxazines; Pancreatic Diseases; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Costs and Cost Analysis; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Liver; Liver Diseases; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Chronic Disease; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Liver Diseases; Male; RNA, Viral; Viral Load | 2007 |
8 other study(ies) available for efavirenz and Liver Dysfunction
| Article | Year |
|---|---|
Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver Diseases; Male; Pilot Projects; Reverse Transcriptase Inhibitors; Severity of Illness Index; Treatment Outcome; Viral Load | 2008 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Liver; Liver Diseases; Male; Nevirapine; Oxazines; Prevalence; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Thailand | 2003 |
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Multivariate Analysis; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Risk; Risk Factors; Transaminases | 2003 |
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index | 2005 |
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genes, MDR; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Liver; Liver Diseases; Male; Nevirapine; Oxazines; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors | 2006 |
Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz.
Topics: Adult; Alkynes; Amodiaquine; Artemisinins; Artesunate; Benzoxazines; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Oxazines; Reference Values; Risk Assessment; Sesquiterpenes; Transaminases | 2007 |
High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Benzoxazines; Bilirubin; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Liver Diseases; Male; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome | 2002 |